Avira License - Cross Site Scripting Web Vulnerability

Document Title:
===============
Avira License - Cross Site Scripting Web Vulnerability


References (Source):
====================
http://www.vulnerability-lab.com/get_content.php?id=916

Avira Case-ID #99287655


Release Date:
=============
2013-04-12


Vulnerability Laboratory ID (VL-ID):
====================================
916


Common Vulnerability Scoring System:
====================================
1.5


Product & Service Introduction:
===============================
Avira Operations GmbH & Co. KG is a German multinational and family-owned antivirus software company. With an estimated 9.6% of the 
global market share according to OPSWAT, and over 100 million customers, Avira is considered the sixth largest antivirus vendor worldwide.
The company supports the Auerbach Stiftung, a foundation created by the company`s founder and CEO, Tjark Auerbach. It promotes charitable 
and social projects as well as the arts, culture and science.

(Copy of the Homepage: http://en.wikipedia.org/wiki/Avira )


Abstract Advisory Information:
==============================
The independent laboratory researcher (Ebrahim Hegazy) discovered a client side web vulnerability in the official Avira license company web application service.


Vulnerability Disclosure Timeline:
==================================
2013-04-08:     Researcher Notification & Coordination
2013-04-10:     Vendor Notification
2013-04-10:     Vendor Response/Feedback
2013-04-12:     Vendor Fix/Patch
2013-04-13:     Public Disclosure


Discovery Status:
=================
Published


Affected Product(s):
====================
Avira
Product: License - Web Application Service 2013 Q1


Exploitation Technique:
=======================
Remote


Severity Level:
===============
Low


Technical Details & Description:
================================
A client side cross site scripting web vulnerability is detected in Googles DoubleClick company web application service.
The vulnerability allows remote attackers to form manipulated urls to inject script code on client side application requests.

The client side cross site scripting web vulnerability is located in the license section when processing to request the 
login file form via GET with a manipulated ff (value) parameter.  

Exploitation of the vulnerability does not require a privileged application user account but low or medium user interaction.
Successful exploitation results in client side cross site requests, unauthorized external redirects, client side phishing, 
client side session hijacking and client side module context manipulation.

Vulnerable Service(s):
				[+] Avira - Licenses (https://license.avira.com)

Vulnerable Module(s):
				[+] login

Vulnerable Parameter(s):
				[+] ff


Proof of Concept (PoC):
=======================
The cross site web vulnerability can be exploited by remote attackers without privileged application user account and with low or medium user interaction.
For demonstration or reproduce ...

Payload: 
"><iframe src="http://test.de/Avira/avira.html" height=345 width=345></iframe>

POC:
https://license.avira.com/en/login?ff=web%22%"><iframe src="http://test.de/Avira/avira.html" height=345 width=345></iframe>%22%3E%3C/iframe%3E


Solution - Fix & Patch:
=======================
Input should be validated as strictly as possible on arrival and user input should be secure encoded with html special chars at any point 
where the context gets copied into application response.


Security Risk:
==============
The security risk of the client side cross site scripting web vulnerability is estimated as low(+).


Credits & Authors:
==================
Vulnerability Laboratory [Research Team] - Ebrahim Hegazy [[email protected]] ([email protected])


Disclaimer & Information:
=========================
The information provided in this advisory is provided as it is without any warranty. Vulnerability-Lab disclaims all warranties, 
either expressed or implied, including the warranties of merchantability and capability for a particular purpose. Vulnerability-
Lab or its suppliers are not liable in any case of damage, including direct, indirect, incidental, consequential loss of business 
profits or special damages, even if Vulnerability-Lab or its suppliers have been advised of the possibility of such damages. Some 
states do not allow the exclusion or limitation of liability for consequential or incidental damages so the foregoing limitation 
may not apply. We do not approve or encourage anybody to break any vendor licenses, policies, deface websites, hack into databases 
or trade with fraud/stolen material.

Domains:    www.vulnerability-lab.com   	- www.vuln-lab.com			       - www.vulnerability-lab.com/register
Contact:    [email protected] 	- [email protected] 	       - [email protected]
Section:    video.vulnerability-lab.com 	- forum.vulnerability-lab.com 		       - news.vulnerability-lab.com
Social:	    twitter.com/#!/vuln_lab 		- facebook.com/VulnerabilityLab 	       - youtube.com/user/vulnerability0lab
Feeds:	    vulnerability-lab.com/rss/rss.php	- vulnerability-lab.com/rss/rss_upcoming.php   - vulnerability-lab.com/rss/rss_news.php

Any modified copy or reproduction, including partially usages, of this file requires authorization from Vulnerability Laboratory. 
Permission to electronically redistribute this alert in its unmodified form is granted. All other rights, including the use of other 
media, are reserved by Vulnerability-Lab Research Team or its suppliers. All pictures, texts, advisories, source code, videos and 
other information on this website is trademark of vulnerability-lab team & the specific authors or managers. To record, list (feed), 
modify, use or edit our material contact ([email protected] or [email protected]) to get a permission.

    				   	Copyright © 2013 | Vulnerability Laboratory